Drugs / Exenatide
Exenatide
Regulatory milestones approvals, filings & regulatory actions · 11 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (4) | US (FDA) | BYETTA | — | 2006-12-22 – 2021-11-04 | fda.gov ↗ |
| Label expansions (5) | US (FDA) | BYDUREON PEN | — | 2015-09-24 – 2021-07-22 | fda.gov ↗ |
| Approved | EU (EMA) | Byetta | — | 2006-11-20 | europa.eu ↗ |
| Approved | US (FDA) | BYETTA | — | 2005-04-28 | fda.gov ↗ |
Trials 220 · started per year
today
US approved 2005
EU approved 2006
7
5
4
6
13
14
23
15
14
8
8
17
20
17
14
10
4
5
5
4
3
1
3
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT02690987 | Aug 2015 → Aug 2019 | alcohol dependence, obesity disorder | Imperial College London | Unknown | No outcome recorded |
| Phase 124 trials | ||||||
| Phase 1 | NCT06252623 | Aug 2024 → Mar 2026 | substance-related disorder | Christopher D. Verrico | Withdrawn | No outcome recorded |
| Phase 1 | NCT04001231 | Jun 2020 → Jul 2021 | type 2 diabetes mellitus | AstraZeneca | Withdrawn | No outcome recorded |
| Phase 1 | NCT03645408 | May 2019 → Jul 2021 | alcohol-related disorders | Boston Medical Center | Terminated | No outcome recorded |
| Phase 1 | NCT03456687 | Jun 2018 → Oct 2020 | Parkinson disease | University of Florida | Completed | No outcome recorded |
| Phase 1 | NCT03199261 | Dec 2016 → Jan 2017 | type 2 diabetes mellitus | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05762744 | Jun 2016 → Nov 2018 | type 2 diabetes mellitus | University of Maryland, Baltimore | Terminated | No outcome recorded |
| Phase 1 | NCT02650479 | Jan → Apr 2016 | — | Intarcia Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT02641990 | Dec 2015 → Feb 2016 | — | Intarcia Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT02641899 | Dec 2015 → Mar 2016 | — | Intarcia Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT02320045 | Nov 2014 → Jul 2015 | impaired renal function disease | Intarcia Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT02302976 | Nov 2014 → Aug 2018 | cocaine dependence | Yale University | Completed | No outcome recorded |
| Phase 1 | NCT01857895 | May → Nov 2013 | obesity disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT02349802 | Feb → Dec 2013 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01855490 | Jan 2012 → Jul 2013 | type 1 diabetes mellitus | Yale University | Completed | No outcome recorded |
| Phase 1 | NCT01297062 | Feb → Apr 2011 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00964262 | Aug 2009 → Oct 2010 | type 2 diabetes mellitus | Peptron, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01798264 | Feb → May 2009 | type 2 diabetes mellitus | Intarcia Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT00672399 | Apr → Jul 2008 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01021527 | Feb → Mar 2008 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT00971659 | Jan → Sep 2008 | type 2 diabetes mellitus | Profil Institute for Metabolic Research GmbH | Completed | No outcome recorded |
| Phase 1 | NCT00612794 | Sep 2007 → May 2008 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00254800 | Nov 2005 → Aug 2006 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00259896 | Oct 2005 → ? | type 2 diabetes mellitus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00517283 | Jan → Jun 2005 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 1/26 trials | ||||||
| Phase 1/2 | NCT02586831 | Jun 2024 | hypoglycemia, type 1 diabetes mellitus | Camillo Ricordi and Jay Skyler | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT04941521 | Jun → Nov 2021 | substance-related disorder | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| Phase 1/2 | NCT02975297 | Jul 2016 → Jan 2020 | — | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| Phase 1/2 | NCT01061775 | Jan 2010 → Jul 2013 | acquired hypothalamic obesity | Children's Hospitals and Clinics of Minnesota | Completed | No outcome recorded |
| Phase 1/2 | NCT00894322 | Apr → Aug 2009 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 1/2 | NCT00882050 | Mar 2009 → Apr 2016 | hyperglycemia, hypoglycemia | Thomas Jefferson University | Completed | No outcome recorded |
| Phase 230 trials | ||||||
| Phase 2 | NCT05356104 | May 2022 → May 2027 expected | cerebrovascular disorder | Chinese University of Hong Kong | Recruiting | No outcome recorded |
| Phase 2 | NCT04431713 | Sep 2020 → Mar 2024 | multiple system atrophy | University College, London | Completed | No outcome recorded |
| Phase 2 | NCT04269642 | Mar 2020 → Sep 2021 | Parkinson disease | Peptron, Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT04305002 | Jan 2020 → Oct 2023 | Parkinson disease | Center for Neurology, Stockholm | Unknown | No outcome recorded |
| Phase 2 | NCT03287076 | Nov 2017 → Oct 2021 | ischemic stroke | Neuroscience Trials Australia | Unknown | No outcome recorded |
| Phase 2 | NCT03017352 | Dec 2016 → Jun 2019 | type 1 diabetes mellitus | Filip Krag Knop | Completed | No outcome recorded |
| Phase 2 | NCT02313220 | Dec 2014 → Mar 2016 | obesity disorder | Uppsala University | Completed | No outcome recorded |
| Phase 2 | NCT02119819 | Apr 2014 → Aug 2015 | type 2 diabetes mellitus | OPKO Health, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01938235 | Feb 2014 → Jul 2017 | myocardial infarction | University Health Network, Toronto | Unknown | No outcome recorded |
| Phase 2 | NCT01928329 | Sep 2013 → Jun 2018 | type 1 diabetes mellitus | Yale University | Completed | No outcome recorded |
| Phase 2 | NCT01484873 | Jun 2012 → Mar 2015 | craniopharyngioma, obesity disorder | Vanderbilt University Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT01255163 | Nov 2010 → Nov 2016 | Alzheimer disease, cognitive impairment with or without cerebellar ataxia | National Institute on Aging (NIA) | Terminated | No outcome recorded |
| Phase 2 | NCT01237197 | Oct 2010 → May 2012 | obesity disorder | University of Minnesota | Completed | No outcome recorded |
| Phase 2 | NCT01174810 | Jul 2010 → Mar 2013 | Parkinson disease | University College, London | Unknown | No outcome recorded |
| Phase 2 | NCT00886626 | May 2009 → Feb 2011 | morbid obesity | University of Minnesota | Completed | No outcome recorded |
| Phase 2 | NCT00701935 | Aug 2008 → Jan 2012 | type 2 diabetes mellitus | AstraZeneca | Terminated | No outcome recorded |
| Phase 2 | NCT01154933 | Apr 2008 → Nov 2011 | type 2 diabetes mellitus | University at Buffalo | Completed | No outcome recorded |
| Phase 2 | NCT00529204 | Oct 2007 → Jul 2009 | NAFLD1 | University of California, Davis | Terminated | No outcome recorded |
| Phase 2 | NCT00500370 | Jun 2007 → Feb 2008 | obesity disorder | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00518115 | Apr 2007 → May 2008 | type 2 diabetes mellitus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00456300 | Mar 2007 → Mar 2009 | type 1 diabetes mellitus | Montefiore Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT00382239 | Sep 2006 → May 2007 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00344851 | Jun 2006 → Jun 2007 | polycystic ovary syndrome | Metabolic Center of Louisiana Research Foundation | Completed | No outcome recorded |
| Phase 2 | NCT00254254 | Feb 2006 → Feb 2007 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00241423 | Oct 2005 → Jun 2007 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00103935 | Feb → Oct 2005 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00099333 | Feb 2004 → Aug 2005 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00085969 | Sep 2003 → Jan 2004 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00064714 | Jul 2003 → Mar 2008 | diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00044694 | Aug 2002 → May 2003 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 2/36 trials | ||||||
| Phase 2/3 | NCT02584582 | Jul → Nov 2015 | type 1 diabetes mellitus | Hvidovre University Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT02432976 | May 2015 → Jan 2017 | — | Centre Hospitalier Universitaire de Besancon | Completed | No outcome recorded |
| Phase 2/3 | NCT01969149 | Jan → Dec 2015 | hyperglycemia | Centre Hospitalier Universitaire de Besancon | Completed | No outcome recorded |
| Phase 2/3 | NCT02157974 | Aug 2014 → Dec 2022 | fatty liver disease, obesity disorder, polycystic ovary syndrome | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 2/3 | NCT01140893 | Nov 2010 → May 2017 | type 2 diabetes mellitus | University Hospital, Caen | Unknown | No outcome recorded |
| Phase 2/3 | NCT00650546 | Aug 2006 → Aug 2010 | NAFLD1 | Indiana University | Completed | No outcome recorded |
| Phase 362 trials | ||||||
| Phase 3 | NCT05347147 | Nov 2022 → Sep 2023 | pseudotumor cerebri | Invex Therapeutics Ltd. | Terminated | No outcome recorded |
| Phase 3 | NCT03671733 | Sep 2018 → Sep 2022 | obesity disorder | Xiangya Hospital of Central South University | Unknown | No outcome recorded |
| Phase 3 | NCT03419624 | Feb 2018 → Apr 2019 | obesity disorder, type 2 diabetes mellitus | University Medical Center Hamburg-Eppendorf | Terminated | No outcome recorded |
| Phase 3 | NCT03060980 | Mar 2017 → Jan 2018 | type 2 diabetes mellitus | Intarcia Therapeutics | Terminated | No outcome recorded |
| Phase 3 | NCT02860923 | Jan 2017 → Jun 2018 | acquired hypothalamic obesity, craniopharyngioma | University Hospital, Bordeaux | Completed | No outcome recorded |
| Phase 3 | NCT02635386 | Mar 2016 → Jul 2020 | obesity disorder, polycystic ovary syndrome | Woman's | Completed | No outcome recorded |
| Phase 3 | NCT02847403 | Feb 2016 → Jul 2019 | cognitive disorder, glucose metabolism disease | Azienda Ospedaliero-Universitaria di Parma | Unknown | No outcome recorded |
| Phase 3 | NCT02638805 | Dec 2015 → Oct 2017 | type 2 diabetes mellitus | Intarcia Therapeutics | Completed | No outcome recorded |
| Phase 3 | NCT02251431 | Nov 2015 → Dec 2019 | chronic kidney disease, diastolic heart failure, type 2 diabetes mellitus | Baylor Research Institute | Completed | No outcome recorded |
| Phase 3 | NCT02229383 | Sep 2014 → Aug 2016 | diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT02229396 | Sep 2014 → Apr 2016 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT02194595 | Sep 2014 → Dec 2021 | type 2 diabetes mellitus | Mount Sinai Hospital, Canada | Completed | No outcome recorded |
| Phase 3 | NCT01785771 | May 2013 → Jan 2018 | type 2 diabetes mellitus | Intarcia Therapeutics | Terminated | No outcome recorded |
| Phase 3 | NCT01455870 | May 2013 → Jul 2015 | type 2 diabetes mellitus | Intarcia Therapeutics | Completed | No outcome recorded |
| Phase 3 | NCT01455857 | Mar 2013 → Aug 2014 | type 2 diabetes mellitus | Intarcia Therapeutics | Completed | No outcome recorded |
| Phase 3 | NCT01455896 | Mar 2013 → Mar 2016 | type 2 diabetes mellitus | Intarcia Therapeutics | Completed | No outcome recorded |
| Phase 3 | NCT01455909 | Feb 2013 → Jul 2014 | type 2 diabetes mellitus | Intarcia Therapeutics | Withdrawn | No outcome recorded |
| Phase 3 | NCT01652729 | Feb 2013 → Apr 2014 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT01455883 | Feb 2013 → Jul 2014 | type 2 diabetes mellitus | Intarcia Therapeutics | Withdrawn | No outcome recorded |
| Phase 3 | NCT01455922 | Feb 2013 → Jul 2014 | type 2 diabetes mellitus | Intarcia Therapeutics | Withdrawn | No outcome recorded |
| Phase 3 | NCT01652716 | Jan 2013 → Aug 2014 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT01554618 | Dec 2011 → May 2020 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT01373216 | Jun 2011 → May 2014 | coronary atherosclerosis, left ventricular failure | Charles University, Czech Republic | Completed | No outcome recorded |
| Phase 3 | NCT02042664 | Jan 2011 → Jan 2015 | diabetes mellitus, obesity disorder | Assistance Publique Hopitaux De Marseille | Completed | No outcome recorded |
| Phase 3 | NCT01144338 | Jun 2010 → Apr 2017 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT01029886 | Jan 2010 → Jan 2011 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT01003184 | Oct 2009 → Jul 2011 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00960661 | Sep 2009 → Aug 2012 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00935532 | Jul 2009 → Sep 2010 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00917267 | Jul 2009 → Sep 2010 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00877890 | Mar → Oct 2009 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00676338 | Nov 2008 → Jul 2010 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00765817 | Oct 2008 → Jan 2010 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00753896 | Oct 2008 → Jul 2009 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00658021 | May 2008 → Apr 2019 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00641056 | Apr 2008 → May 2009 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00577824 | Jan → Nov 2008 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00603239 | Jan 2008 → Jul 2009 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00637273 | Jan 2008 → Feb 2009 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00516074 | Sep 2007 → Apr 2008 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00516048 | Aug 2007 → Apr 2008 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00434954 | Feb 2007 → Jun 2009 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00359879 | Sep 2006 → Jul 2007 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00381342 | Sep 2006 → Sep 2007 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00359762 | Sep 2006 → Mar 2011 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00375492 | Sep 2006 → Feb 2008 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00360334 | Jun 2006 → Apr 2008 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00313001 | Apr 2006 → Jul 2007 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT00324363 | Jan 2006 → Apr 2007 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00135330 | Oct 2005 → Jul 2008 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00099619 | Sep 2004 → Aug 2005 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00097500 | Sep 2004 → Dec 2009 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00099320 | May 2004 → Aug 2005 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT01876849 | Dec 2003 → Jul 2008 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00082407 | Nov 2003 → Jul 2008 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00082381 | Jun 2003 → Jul 2008 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00111540 | Nov 2002 → Sep 2006 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT01789957 | Sep 2002 → Jun 2004 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00044668 | Aug 2002 → Sep 2005 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00035984 | May 2002 → Aug 2003 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00039013 | Mar 2002 → Jun 2003 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00039026 | Feb 2002 → Aug 2003 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 471 trials | ||||||
| Phase 4 | NCT05482789 | Apr 2023 → Dec 2025 overdue | gestational diabetes | Maisa N. Feghali, MD | Recruiting | No outcome recorded |
| Phase 4 | NCT04307797 | Jan → Oct 2022 | obesity disorder, type 2 diabetes mellitus | Cambridge University Hospitals NHS Foundation Trust | Completed | No outcome recorded |
| Phase 4 | NCT04897802 | Sep 2021 → Apr 2024 | central diabetes insipidus, hypothalamic disorder, panhypopituitarism, psychiatric disorder | Sant Pau Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT04969627 | Jan 2021 → Jan 2022 | polycystic ovary syndrome | Bing He | Completed | No outcome recorded |
| Phase 4 | NCT04135287 | Mar 2020 → Mar 2023 | type 2 diabetes mellitus | Dasman Diabetes Institute | Unknown | No outcome recorded |
| Phase 4 | NCT04027023 | Oct 2019 → Apr 2021 | type 2 diabetes mellitus | Sciema UG | Unknown | No outcome recorded |
| Phase 4 | NCT04029272 | Jul 2019 → Feb 2020 | polycystic ovary syndrome | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03970044 | Jul 2019 → Jun 2021 | type 2 diabetes mellitus | Consano Clinical Research, LLC | Completed | No outcome recorded |
| Phase 4 | NCT03383068 | Jan → Dec 2018 | glucose intolerance, polycystic ovary syndrome | RenJi Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03352869 | Nov 2017 → Jul 2018 | glucose intolerance, polycystic ovary syndrome | RenJi Hospital | Completed | No outcome recorded |
| Phase 4 | NCT03361098 | Sep 2017 → Nov 2019 | obesity disorder, type 2 diabetes mellitus | Amsterdam UMC, location VUmc | Completed | No outcome recorded |
| Phase 4 | NCT03160261 | Sep → Dec 2017 | — | University of Tartu | Completed | No outcome recorded |
| Phase 4 | NCT03804411 | Aug 2017 → Mar 2020 | type 2 diabetes mellitus | Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health | Unknown | No outcome recorded |
| Phase 4 | NCT03151005 | Jul 2017 → Apr 2021 | obesity disorder, polycystic ovary syndrome | Xinqiao Hospital of Chongqing | Completed | No outcome recorded |
| Phase 4 | NCT03018665 | Feb 2017 → Dec 2021 | type 2 diabetes mellitus | The First Hospital of Jilin University | Unknown | No outcome recorded |
| Phase 4 | NCT03029351 | Jan 2017 → Jul 2019 | kidney disorder, type 2 diabetes mellitus | University at Buffalo | Terminated | No outcome recorded |
| Phase 4 | NCT02793154 | Sep 2016 → Mar 2017 | type 2 diabetes mellitus | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 4 | NCT02802514 | Sep 2016 → Aug 2017 | diabetes mellitus | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 4 | NCT03002675 | Aug 2016 → Jun 2018 | obesity disorder | Ingrid Jazet | Unknown | No outcome recorded |
| Phase 4 | NCT02811484 | Jun 2016 → Jun 2018 | type 2 diabetes mellitus | Weill Medical College of Cornell University | Withdrawn | No outcome recorded |
| Phase 4 | NCT02690883 | Apr 2016 → Dec 2019 | diabetic kidney disease | Nanfang Hospital, Southern Medical University | Completed | No outcome recorded |
| Phase 4 | NCT02533453 | Jan → Dec 2016 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT02621489 | Dec 2015 → Aug 2022 | atherosclerosis, coronary restenosis, diabetes mellitus | Karolinska Institutet | Completed | No outcome recorded |
| Phase 4 | NCT02584075 | Nov 2015 → Nov 2017 | coronary artery disorder | Beijing Chao Yang Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02449603 | Nov 2015 → Apr 2018 | type 2 diabetes mellitus | Xijing Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02467920 | Aug 2015 → Dec 2017 | type 2 diabetes mellitus | Huazhong University of Science and Technology | Completed | No outcome recorded |
| Phase 4 | NCT02058940 | Aug 2015 → Aug 2017 | brain injury | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| Phase 4 | NCT02303730 | Mar 2015 → Nov 2017 | NAFLD1, type 2 diabetes mellitus | Fudan University | Completed | No outcome recorded |
| Phase 4 | NCT02380521 | Jan 2015 → Jul 2016 | type 2 diabetes mellitus | University of Palermo | Completed | No outcome recorded |
| Phase 4 | NCT02288273 | Dec 2014 → Aug 2015 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT02501850 | Oct 2014 → Jul 2015 | type 2 diabetes mellitus | Hospital Universitari Vall d'Hebron Research Institute | Unknown | No outcome recorded |
| Phase 4 | NCT02417142 | Sep 2014 → Jul 2019 | schizoaffective disorder, schizophrenia | University of Massachusetts, Worcester | Completed | No outcome recorded |
| Phase 4 | NCT02162550 | Jun 2014 → Apr 2019 | type 2 diabetes mellitus | Phoenix VA Health Care System | Unknown | No outcome recorded |
| Phase 4 | NCT02160990 | Jun 2014 → Mar 2015 | obesity disorder | Mayo Clinic | Completed | No outcome recorded |
| Phase 4 | NCT02170324 | Jun 2014 → Jul 2015 | obesity disorder | Xiang Guang-da | Completed | No outcome recorded |
| Phase 4 | NCT02104739 | Apr 2014 → Mar 2017 | obesity disorder, prediabetes syndrome | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| Phase 4 | NCT02072096 | Feb 2014 → Oct 2015 | type 2 diabetes mellitus | Eli Lilly and Company | Terminated | No outcome recorded |
| Phase 4 | NCT02129985 | Feb 2014 → Jun 2015 | type 2 diabetes mellitus | xiaolong zhao | Unknown | No outcome recorded |
| Phase 4 | NCT00572689 | Aug 2013 → Aug 2015 | gestational diabetes | Georgetown University | Withdrawn | No outcome recorded |
| Phase 4 | NCT01744236 | Apr 2013 → Aug 2015 | type 2 diabetes mellitus | Amsterdam UMC, location VUmc | Completed | No outcome recorded |
| Phase 4 | NCT01791465 | Mar 2013 → Dec 2014 | HIV infectious disease, diabetes mellitus | Vanderbilt University | Terminated | No outcome recorded |
| Phase 4 | NCT01818648 | Mar 2013 → Jan 2014 | short bowel syndrome | Mayo Clinic | Withdrawn | No outcome recorded |
| Phase 4 | NCT03297879 | Jan 2013 → Feb 2016 | type 2 diabetes mellitus | Beijing Chao Yang Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01524705 | Aug 2012 → Jul 2014 | type 2 diabetes mellitus | University of Washington | Completed | No outcome recorded |
| Phase 4 | NCT01776788 | Aug 2012 → Feb 2015 | type 2 diabetes mellitus | The First Affiliated Hospital of Xiamen University | Completed | No outcome recorded |
| Phase 4 | NCT01590433 | Mar 2012 → Jan 2019 | obesity disorder | Jody Dushay | Completed | No outcome recorded |
| Phase 4 | NCT01381926 | Feb 2011 → Aug 2015 | bone remodeling disease, type 2 diabetes mellitus | University of Alabama at Birmingham | Terminated | No outcome recorded |
| Phase 4 | NCT01270191 | Nov 2010 → Dec 2014 | type 2 diabetes mellitus | Taipei Veterans General Hospital, Taiwan | Unknown | No outcome recorded |
| Phase 4 | NCT01181986 | Aug 2010 → Dec 2012 | type 2 diabetes mellitus | Carl T. Hayden VA Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT01588418 | Jul 2010 → Jul 2015 | diabetes mellitus, glucose intolerance | The University of Texas Health Science Center at San Antonio | Completed | No outcome recorded |
| Phase 4 | NCT01951651 | Apr 2010 → Oct 2012 | type 2 diabetes mellitus | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT01269047 | Aug 2009 → Aug 2016 | type 1 diabetes mellitus | Albert Einstein College of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT00799435 | Jul 2009 → Apr 2012 | diastolic heart failure, type 2 diabetes mellitus | Baylor College of Medicine | Terminated | No outcome recorded |
| Phase 4 | NCT00766857 | May 2009 → Dec 2012 | congestive heart failure, type 2 diabetes mellitus | Amsterdam UMC, location VUmc | Completed | No outcome recorded |
| Phase 4 | NCT00870194 | Mar 2009 → Apr 2010 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT01107717 | Jan 2009 → Feb 2023 | type 2 diabetes mellitus | The University of Texas Health Science Center at San Antonio | Completed | No outcome recorded |
| Phase 4 | NCT00845507 | Dec 2008 → Jul 2015 | — | University of Cincinnati | Completed | No outcome recorded |
| Phase 4 | NCT00845559 | Aug 2008 → Mar 2010 | cardiovascular disorder, glucose intolerance, obesity disorder | Yale University | Withdrawn | No outcome recorded |
| Phase 4 | NCT00729326 | Aug 2008 → Oct 2009 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT00736229 | Aug 2008 → Jun 2011 | acute coronary syndrome, hyperglycemia, myocardial infarction | Saint Luke's Health System | Completed | No outcome recorded |
| Phase 4 | NCT00948168 | Jul 2008 → Jul 2009 | type 2 diabetes mellitus | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Completed | No outcome recorded |
| Phase 4 | NCT01435980 | Feb 2008 → Jan 2016 | type 2 diabetes mellitus | Wu Qinan | Unknown | No outcome recorded |
| Phase 4 | NCT01006889 | Jan 2008 → Dec 2009 | NAFLD1, type 2 diabetes mellitus | University of Florida | Completed | No outcome recorded |
| Phase 4 | NCT00623545 | Jan 2008 → Apr 2010 | — | University of Wisconsin, Madison | Completed | No outcome recorded |
| Phase 4 | NCT00546728 | Oct 2007 → Jul 2011 | glucose intolerance | St. Paul Heart Clinic | Completed | No outcome recorded |
| Phase 4 | NCT01432405 | Jun 2007 → Jul 2008 | type 2 diabetes mellitus | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT00845182 | Jun 2007 → Jul 2010 | glucose intolerance, type 2 diabetes mellitus | The University of Texas Health Science Center at San Antonio | Completed | No outcome recorded |
| Phase 4 | NCT00477581 | May → Sep 2007 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT00456885 | Apr 2007 → Sep 2010 | glucose intolerance, obesity disorder | Beth Israel Deaconess Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00974272 | Aug 2006 → Nov 2008 | glucose intolerance, type 2 diabetes mellitus | Carl T. Hayden VA Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00353834 | Aug 2006 → Sep 2010 | type 2 diabetes mellitus | Joslin Diabetes Center | Completed | No outcome recorded |
| Phase not applicable20 trials | ||||||
| — | NCT06256419 | Jan 2024 → Jan 2028 expected | type 2 diabetes mellitus | The Affiliated Hospital of Xuzhou Medical University | Recruiting | No outcome recorded |
| — | NCT04909333 | Apr 2021 → Apr 2024 | hyperinsulinemic hypoglycemia | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| — | NCT05037045 | Jan 2019 → Oct 2023 | type 2 diabetes mellitus | The Affiliated Hospital of Xuzhou Medical University | Completed | No outcome recorded |
| — | NCT02673931 | Feb 2016 → Sep 2024 overdue | aortic valve disorder, brain injury, cardiogenic shock, coronary artery disorder +2 | Rigshospitalet, Denmark | Active not recruiting | No outcome recorded |
| — | NCT02887625 | Feb 2015 → May 2017 | type 2 diabetes mellitus | Dr. Muhammad Abdulghani | Unknown | No outcome recorded |
| — | NCT02344641 | Jan 2015 → Dec 2016 | heart failure, type 2 diabetes mellitus | Chinese Academy of Medical Sciences, Fuwai Hospital | Unknown | No outcome recorded |
| — | NCT02118376 | Aug → Dec 2014 | obesity disorder | Shanghai 10th People's Hospital | Unknown | No outcome recorded |
| — | NCT02442791 | Jun 2014 → Jun 2016 | cardiac arrest | Jesper Kjaergaard | Completed | No outcome recorded |
| — | NCT01783717 | Dec 2012 → Jan 2015 | acquired hypothalamic obesity, diabetes mellitus | Huashan Hospital | Unknown | No outcome recorded |
| — | NCT01444898 | Mar 2012 → May 2013 | Prader-Willi syndrome | Children's Hospital Los Angeles | Completed | No outcome recorded |
| — | NCT01687582 | Jan → Dec 2012 | psoriasis, type 2 diabetes mellitus | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Completed | No outcome recorded |
| — | NCT01281228 | Sep 2011 → Oct 2013 | obesity disorder, type 2 diabetes mellitus | Amsterdam UMC, location VUmc | Completed | No outcome recorded |
| — | NCT01302327 | Mar 2011 → Mar 2013 | Wolfram syndrome, diabetes mellitus | Hadassah Medical Organization | Withdrawn | No outcome recorded |
| — | NCT01575301 | Mar 2011 → Jul 2015 | diabetes mellitus | University of Dundee | Completed | No outcome recorded |
| — | NCT01364584 | Oct 2010 → Dec 2014 | type 2 diabetes mellitus | University of Colorado, Denver | Completed | No outcome recorded |
| — | NCT01136798 | Jun 2010 → Sep 2016 | sleep apnea syndrome, type 2 diabetes mellitus | University of Chicago | Completed | No outcome recorded |
| — | NCT01056549 | Jan 2010 → Sep 2011 | hyperlipidemia | University Health Network, Toronto | Completed | No outcome recorded |
| — | NCT00775684 | Oct 2008 → Nov 2012 | prediabetes syndrome, type 2 diabetes mellitus | University of Pennsylvania | Completed | No outcome recorded |
| — | NCT00855439 | Jun 2008 → May 2014 | diabetic polyneuropathy, type 2 diabetes mellitus | University of Michigan | Completed | No outcome recorded |
| — | NCT00551343 | Oct 2007 → Sep 2008 | Prader-Willi syndrome | Garvan Institute of Medical Research | Completed | No outcome recorded |
Also used as a comparator or background therapy in 68 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 111 trials | ||||||
| Phase 1 | NCT05670379 Comparator | Dec 2024 → Aug 2025 | morbid obesity, type 2 diabetes mellitus | Vivani Medical, Inc | Completed | No outcome recorded |
| Phase 1 | NCT03167411 Comparator | May → Jun 2017 | type 2 diabetes mellitus | Theracos | Completed | No outcome recorded |
| Phase 1 | NCT02685852 Comparator | Feb 2016 → Jul 2019 | hyperinsulinemic hypoglycemia | University of Minnesota | Completed | No outcome recorded |
| Phase 1 | NCT03059719 Comparator | Apr 2015 → Sep 2016 | type 2 diabetes mellitus | PegBio Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01843127 Comparator | Apr → Sep 2013 | type 2 diabetes mellitus | Gilead Sciences | Completed | No outcome recorded |
| Phase 1 | NCT01664624 Comparator | Jul → Nov 2012 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01501084 Comparator | Dec 2011 → Dec 2012 | obesity disorder | University of California, Los Angeles | Completed | No outcome recorded |
| Phase 1 | NCT00782418 Comparator | Sep 2008 → Feb 2009 | abnormality of glucagon secretion | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT00642538 Comparator | Feb → Sep 2008 | type 2 diabetes mellitus | Mannkind Corporation | Completed | No outcome recorded |
| Phase 1 | NCT02084654 Comparator | Nov 2007 → Oct 2012 | prediabetes syndrome | Stanford University | Completed | No outcome recorded |
| Phase 1 | NCT00508287 Comparator | Aug → Nov 2007 | type 2 diabetes mellitus | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT01573806 Comparator | Oct 2012 → Oct 2014 | glucose metabolism disease, infectious disease with sepsis, multiple organ dysfunction syndrome | Seattle Children's Hospital | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT00566813 Comparator | Nov 2004 → Jul 2010 | type 1 diabetes mellitus | University of Illinois at Chicago | Completed | No outcome recorded |
| Phase 29 trials | ||||||
| Phase 2 | NCT05610800 Comparator | Dec 2022 → Nov 2025 | — | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| Phase 2 | NCT03232112 Comparator | Aug 2017 → Mar 2020 | alcohol dependence | Anders Fink-Jensen, MD, DMSci | Completed | No outcome recorded |
| Phase 2 | NCT02838589 Comparator | Aug 2016 → Feb 2017 | stroke disorder | Christina Kruuse | Completed | No outcome recorded |
| Phase 2 | NCT02829502 Comparator | Aug 2016 → Aug 2023 | ischemic stroke | Christina Kruuse | Unknown | No outcome recorded |
| Phase 2 | NCT02496611 Comparator | Dec 2015 → Aug 2020 | morbid obesity | University of Minnesota | Completed | No outcome recorded |
| Phase 2 | NCT02794402 Comparator | Sep 2015 → Sep 2016 | obesity disorder | Uppsala University | Completed | No outcome recorded |
| Phase 2 | NCT01971242 Comparator | Jun 2014 → May 2016 | Parkinson disease | University College, London | Completed | No outcome recorded |
| Phase 2 | NCT01104701 Comparator | May → Dec 2010 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00943917 Comparator | Aug 2009 → Aug 2010 | type 2 diabetes mellitus | Intarcia Therapeutics | Completed | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT02735031 Comparator | Feb 2017 → Mar 2018 | hypoglycemia, type 1 diabetes mellitus | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 2/3 | NCT00747968 Comparator | Feb → Nov 2010 | type 2 diabetes mellitus | University of Aarhus | Completed | No outcome recorded |
| Phase 2/3 | NCT00872378 Comparator | Feb 2009 → Dec 2010 | morbid obesity | Advanced Specialty Care | Unknown | No outcome recorded |
| Phase 316 trials | ||||||
| Phase 3 | NCT04520490 Comparator | Jan 2021 → Aug 2025 overdue | — | Seattle Children's Hospital | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04232969 Comparator | Jan 2020 → Feb 2024 | Parkinson disease | University College, London | Completed | No outcome recorded |
| Phase 3 | NCT02787551 Comparator | Jul 2016 → May 2018 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT02404376 Comparator | Mar 2016 → Aug 2019 | ST-elevation myocardial infarction | Hospital Universitari Vall d'Hebron Research Institute | Completed | No outcome recorded |
| Phase 3 | NCT02664441 Comparator | Mar 2016 → Mar 2020 | acquired hypothalamic obesity | Seattle Children's Hospital | Completed | No outcome recorded |
| Phase 3 | NCT01885208 Comparator | Dec 2013 → Jul 2015 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT01794429 Comparator | Feb 2013 → Jun 2015 | metabolic syndrome X, obesity disorder, schizophrenia | Bjorn H. Ebdrup | Completed | No outcome recorded |
| Phase 3 | NCT01676116 Comparator | Aug 2012 → Mar 2014 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT01064687 Comparator | Feb 2010 → Nov 2011 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT01254123 Comparator | Nov 2009 → ? | acute myocardial infarction | Amsterdam UMC, location VUmc | Unknown | No outcome recorded |
| Phase 3 | NCT00856609 Comparator | Mar 2009 → Sep 2016 | obesity disorder | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
| Phase 3 | NCT00717457 Comparator | Jul 2008 → Mar 2011 | type 2 diabetes mellitus | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT00707031 Comparator | Jun 2008 → Nov 2010 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00679042 Background | Sep 2007 → Jul 2017 overdue | type 1 diabetes mellitus | CellTrans Inc. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT00518882 Comparator | Aug 2007 → Apr 2008 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT00308139 Comparator | Apr 2006 → Jul 2008 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 417 trials | ||||||
| Phase 4 | NCT06449235 Comparator | Sep 2024 → Apr 2025 overdue | type 2 diabetes mellitus | Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT03331289 Comparator | Feb 2018 → Mar 2022 | type 2 diabetes mellitus | The University of Texas Health Science Center at San Antonio | Completed | No outcome recorded |
| Phase 4 | NCT02981069 Comparator | Dec 2017 → Jul 2022 | type 2 diabetes mellitus | The University of Texas Health Science Center at San Antonio | Completed | No outcome recorded |
| Phase 4 | NCT03444142 Comparator | Nov 2017 → Nov 2021 | type 2 diabetes mellitus | University of Guadalajara | Unknown | No outcome recorded |
| Phase 4 | NCT03007329 Comparator | Mar 2017 → Nov 2019 | fatty liver disease, type 2 diabetes mellitus | Medical University of Vienna | Completed | No outcome recorded |
| Phase 4 | NCT02455076 Comparator | Sep 2015 → Mar 2018 | type 2 diabetes mellitus | Emory University | Completed | No outcome recorded |
| Phase 4 | NCT02325960 Comparator | Jan 2015 → Jul 2016 | type 2 diabetes mellitus | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Completed | No outcome recorded |
| Phase 4 | NCT02092597 Comparator | Oct 2013 → Oct 2015 | type 2 diabetes mellitus | Charles University, Czech Republic | Completed | No outcome recorded |
| Phase 4 | NCT01269034 Comparator | Dec 2010 → Jan 2017 | type 1 diabetes mellitus | Albert Einstein College of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT01235819 Comparator | Nov 2010 → Sep 2011 | type 1 diabetes mellitus | Command Hospital, India | Completed | No outcome recorded |
| Phase 4 | NCT01580514 Comparator | Sep 2009 → Aug 2011 | myocardial infarction | Kyunghee University Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00950677 Comparator | Jul 2009 → May 2011 | type 2 diabetes mellitus | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT01700075 Comparator | Jan → Dec 2009 | atherosclerosis, coronary artery disorder, myocardial infarction, type 2 diabetes mellitus | Nazarbayev University | Completed | No outcome recorded |
| Phase 4 | NCT00835848 Comparator | Jan → Dec 2009 | myocardial infarction | Rigshospitalet, Denmark | Completed | No outcome recorded |
| Phase 4 | NCT01208649 Comparator | Jul 2008 → Sep 2010 | NAFLD1 | Ruhr University of Bochum | Completed | No outcome recorded |
| Phase 4 | NCT01076842 Comparator | Apr 2008 → Apr 2011 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 4 | NCT00667732 Comparator | Mar 2007 → Oct 2009 | type 2 diabetes mellitus | Oregon Health and Science University | Completed | No outcome recorded |
| Phase not applicable10 trials | ||||||
| — | NCT03835013 Comparator | Feb 2019 → Nov 2021 | cardiovascular disorder | Cambridge University Hospitals NHS Foundation Trust | Completed | No outcome recorded |
| — | NCT02962492 Comparator | Nov 2016 → Feb 2021 | — | University at Buffalo | Completed | No outcome recorded |
| — | NCT02244164 Comparator | Oct 2014 → Feb 2023 | type 2 diabetes mellitus | Erasme University Hospital | Terminated | No outcome recorded |
| — | NCT01677104 Comparator | Aug 2012 → Jul 2014 | obesity disorder, type 2 diabetes mellitus | Katarina Kos | Completed | No outcome recorded |
| — | NCT01473147 Comparator | Oct 2011 → Jun 2013 | type 2 diabetes mellitus | Chang Gung Memorial Hospital | Completed | No outcome recorded |
| — | NCT01429506 Comparator | Jan 2011 → Aug 2012 | diabetes mellitus, obesity disorder | Post Graduate Institute of Medical Education and Research, Chandigarh | Completed | No outcome recorded |
| — | NCT01147627 Comparator | Aug 2010 → Aug 2012 | type 2 diabetes mellitus | Sun Yat-sen University | Completed | No outcome recorded |
| — | NCT01089569 Comparator | Apr 2010 → May 2013 | type 2 diabetes mellitus | HealthPartners Institute | Completed | No outcome recorded |
| — | NCT01046721 Comparator | Sep 2009 → Dec 2012 | type 2 diabetes mellitus | University of Nottingham | Completed | No outcome recorded |
| — | NCT00744224 Comparator | Feb 2009 → Jan 2010 | glucose metabolism disease | Amsterdam UMC, location VUmc | Completed | No outcome recorded |
Press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2016-06-23 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Settles Patent Litigation with AstraZeneca Allowing Teva to Commercialize Its Generic Version of Byetta® (Exenatide Injection) in the United States tevapharm.com ↗ |
| 2008-06-06 | Novo Nordisk A/S | Klinisk studie viser, at liraglutide giver statistisk signifikant bedre blodsukkerregulering end exenatide novonordisk.com ↗ |
| 2008-06-06 | Novo Nordisk A/S | Clinical study shows liraglutide provides statistically significantly better blood glucose control than exenatide novonordisk.com ↗ |
Evidence & citations 29 cited values
Every value below carries the sentence it was read from. 302 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Exenatide | “Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic...” PMID 27106272 ↗ May 2016268“This trial has been designed to evaluate the efficacy and safety of a new formulation of exenatide (Presendin) in the reduction of intracranial pressure (ICP) in patients with IIH.” NCT05347147 ↗ “Exendin-4 (or Exenatide) is a medication currently used to treat diabetes that has shown promising results in animal and cellular models of Alzheimer's disease.” NCT01255163 ↗ “This is a retrospective cohort study of patients with T2DM who were treated with exenatide twice daily as a part of their diabetes care for at least 12 months.” NCT06256419 ↗ “This is a retrospective cohort study of patients with T2DM who were treated with exenatide twice daily as a part of their diabetes care for at least 12 months.” NCT05037045 ↗ “exenatide subcutaneously 5 mcg pre-transplant and twice daily for I week, then increased to 10-mcg twice daily for 6 months after the last islet transplant.” NCT00566813 ↗ “Chemical Name: GLP-1 Receptor Agonists (GLP1RA) (e.g., Exenatide, Liraglutide, Dulaglutide, Semaglutide) Class: Glucagon-Like Peptide-1 Receptor Agonists” NCT06449235 ↗ “ITCA 650 osmotic mini pump delivering exenatide 20 mcg/day for 14 days, followed by ITCA 650 osmotic mini pump delivering exenatide 60 mcg/day.” NCT02641899 ↗ “Exenatide (GLP-1) has been approved by the Food and Drug Administration (FDA) to treat patients with Type 2 Diabetes (T2D) and obesity.” NCT04269642 ↗ “Antihyperglycemic drugs: biguanides "Metformin" - 0.5 g two or tree times per day, or "Exenatide" - 5-10 µg per day.” NCT01700075 ↗ “Exenatide for weight-loss maintenance in adolescents with severe obesity: A randomized, placebo-controlled trial.” PMID 35403350 ↗ Apr 2022 “GLP-1 Receptor Agonist(e.g. exenatide, liraglutide) have the effects of lowering blood sugar and weight control” NCT03151005 ↗ “exenatide QW (2-mg subcutaneous injection) plus once-daily dapagliflozin (10-mg oral tablet)” PMID 30082326 ↗ Aug 2018 “Exenatide 5-mcg s.c. bid for 1 week, then 10 mcg bid for 6 months after each transplant” NCT00679042 ↗ “2mg once weekly via subcutaneous injection for 78 weeks for Bydureon bcise (exenatide)” NCT05356104 ↗ “ITCA 650 osmotic mini pump delivering exenatide 20/60 mcg/day and Levora® for 28 days” NCT02641990 ↗ “Exenatide-extended release (BYDUREON™) 2 mg subcutaneously once per week x 38 weeks” NCT02251431 ↗ “single dose administration of exenatide 5ug by subcutaneous injection” NCT01021527 ↗ “Single dose of subcutaneous injection of 5 μg exenatide (Byetta).” NCT02838589 ↗ “ITCA 650 osmotic mini pump delivering exenatide 20/60 mcg/day” NCT02638805 ↗ “ITCA 650 osmotic mini-pump delivering exenatide 20/60 mcg/day” NCT03060980 ↗ “Exenatide 10 mcg BD, Metformin 2-3 gm/day, 800 Kcal diet” NCT01429506 ↗ “Byetta® (Exenatide), 10 ug, bid, subcutaneous injection” NCT03167411 ↗ “Treatment with liraglutide, exenatide or lixisenatide” NCT02501850 ↗ “subgroup 6A- addition of exenatide 20 μg/day” NCT03804411 ↗ “Liraglutide, Victoza or Exenatide, Byetta.” NCT01687582 ↗ “weekly exenatide (bydureon) 2 mg per week” NCT04135287 ↗ “ITCA 650 is exenatide in DUROS” NCT01455922 ↗ “ITCA 650 is exenatide in DUROS” NCT01455896 ↗ “ITCA 650 is exenatide in DUROS” NCT01455857 ↗ “ITCA 650 is exenatide in DUROS” NCT01455870 ↗ “10µg Exenatide, prandial” NCT00642538 ↗ “- exenatide (Byetta®)” NCT02244164 ↗ “exenatide (15 µg/day)” NCT04027023 ↗ “AC2993 (exenatide)” NCT00064714 ↗ “exenatide in DUROS” NCT01455909 ↗ “exenatide in DUROS” NCT01455883 ↗ “Exenatide (Byetta)” NCT01677104 ↗ |
| Known as | - exenatide extended-release (Bydureon). | “- exenatide extended-release (Bydureon®).” NCT02244164 ↗ |
| Known as | AC2993 | “effects on glucose control of AC2993 as compared to placebo in patients with type 2 diabetes” NCT00035984 ↗7“AC2993 5mcg (0.02 mL) for 4 weeks” NCT00039026 ↗ “AC2993 5 mcg (0.02 mL)” NCT00039013 ↗ “Exenatide (AC2993)” NCT00082381 ↗ |
| Known as | Bydureon | “Exenatide will be purchased commercially as Bydureon® for subcutaneous (SC) injection and administered at a dose of 2 mg once a week for a total of 6 weeks.” NCT04941521 ↗15“Exenatide will be purchased commercially as Bydureon® for subcutaneous injection and administered at 2 mg once a week for 6 weeks.” NCT06252623 ↗ “A Phase II Trial to Examine the Effect of Subcutaneous Exenatide (Bydureon®) on Glucose Control in Patients With Type I Diabetes” NCT01928329 ↗ “Bydureon® (exenatide) is supplied as powder and solvent for prolonged release injection (once-weekly).” NCT03232112 ↗ “Exenatide-extended release (BYDUREON™) 2 mg subcutaneously once per week x 38 weeks” NCT02251431 ↗ “pioglitazone (actos) 30 mg per day and exenatide (bydureon) 2 mg per week” NCT02887625 ↗ “Bydureon (Exenatide once weekly) injections s.c.” NCT02794402 ↗ “weekly exenatide (bydureon) 2 mg per week” NCT04135287 ↗ “Exenatide extended release 2mg (Bydureon)” NCT04232969 ↗ “Exenatide Pen Injector [Bydureon]” NCT04431713 ↗ “Exenatide 2 mg [Bydureon]” NCT03419624 ↗ |
| Known as | Bydureon BCise (exenatide extended release) | “Bydureon BCise (exenatide extended release)” NCT05670379 ↗ |
| Known as | Byetta | “NovoLog® Mix 70/30 (Biphasic Insulin Aspart 70/30) BID and QD vs. Byetta™ Exenatide) BID on Glycemic Control: A Multicenter, 24-Week, Open-Label, Parallel Group Study in...” NCT00313001 ↗21“Drug: Byetta and Glucophage Generic name: Exenatide Dosage form: Exenatide 5ug and 10ug; Metformin 500mg Dosage: Exenatide10-20ug/day; Metformin 1500-2000mg/day Frequency:...” NCT04969627 ↗ “A Pilot Study to Determine the Effects of a Single Dose of Exenatide (Byetta ®) on the Acute Metabolic Responses to a Mixed Meal or Intravenous Glucose Tolerance Test in...” NCT01855490 ↗ “A new medicine called exenatide (Byetta) has been found to reduce body weight, as well as, improve abnormal glucose metabolism in diabetics.” NCT00344851 ↗ “The incretin mimetic Exenatide (Byetta®) exhibits strong glucoregulatory activities through its multiple biological effects.” NCT01208649 ↗ “They were administered 17.4 μg exenatide (Byetta) or placebo over a 6-hour and 15-minute infusion” PMID 27838646 ↗ Nov 2016 “25 μg Byetta (Lilly, Exenatide) and 0.1% human albumine are added to 250 ml isotonic NaCl.” NCT00835848 ↗ “pre-trial treatment of exenatide (Byetta®) (GLP-1 receptor agonist) + OAD” NCT01676116 ↗ “The medicines are called Symlin (pramlintide) and Byetta (exenatide).” NCT00950677 ↗ “Single dose of subcutaneous injection of 5 μg exenatide (Byetta).” NCT02838589 ↗ “Byetta® (Exenatide), 10 ug, bid, subcutaneous injection” NCT03167411 ↗ “Liraglutide, Victoza or Exenatide, Byetta.” NCT01687582 ↗ “25 microg Byetta (Lilly, Exenatide).” NCT02673931 ↗ “exenatide BYETTA® (Amylin-Lilly)” NCT01580514 ↗ “Exenatide injection(Byetta)” NCT03059719 ↗ “exenatide (Byetta)” NCT00948168 ↗ “Byetta (Exenatide)” NCT02584075 ↗ “Byetta (exenatide)” NCT00856609 ↗ “Byetta, Exenatide” NCT00747968 ↗ |
| Known as | EQW | “OBJECTIVE: We recently reported that after 26 weeks, exenatide once weekly (EQW) resulted in superior A1C reduction, reduced hypoglycemia, and progressive weight loss compared...” PMID 22357185 ↗ Feb 20124“The Diabetes Therapy Utilization: Researching Changes in A1C, Weight, and Other Factors Through Intervention With Exenatide Once Weekly (DURATION) program comprised 6...” PMID 23748506 ↗ May 2013 “The efficacy of once-weekly exenatide (EQW) and dapagliflozin (DAPA) alone and coadministered” PMID 34097062 ↗ Sep 2021 “once-weekly exenatide (EQW) in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).” PMID 35761271 ↗ Jun 2022 “The safety and efficacy of exenatide once weekly (EQW) is overall well established.” PMID 32306296 ↗ Apr 2020 |
| Known as | EXE | “AIMS: To investigate the potential synergistic effects of combined exenatide (EXE) and dapagliflozin (DAPA) versus (PLAC) placebo and DAPA on hepatocellular lipid (HCL)...” PMID 33464703 ↗ Feb 20213“treatment with the glucagon-like peptide receptor agonist (GLP-1 RA) exenatide (EXE) could prevent GC-induced glucose intolerance.” PMID 21216851 ↗ Jan 2011 “adjunctive therapy of exenatide (EXE)” PMID 20357372 ↗ Mar 2010 “exenatide (EXE), 5 μg s.c.” PMID 35235659 ↗ Jun 2022 |
| Known as | Exenatide (Byeta) | “Exenatide (Byeta)” NCT00845507 ↗ |
| Known as | Exenatide (Byetta) | “- exenatide (Byetta®)” NCT02244164 ↗ |
| Known as | Exenatide = BYETTA (R) | “Exenatide = BYETTA (R)” NCT01140893 ↗ |
| Known as | exenatide acetate | “The drug part will exclude the active pharmaceutical ingredient (exenatide acetate) and the diluent part will be the same as the active treatment diluent.” NCT05347147 ↗ |
| Known as | Exenatide extended-release | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02119819 ↗ |
| Known as | Exenatide extended-release (ER) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02104739 ↗ |
| Known as | exenatide XR | “Those who achieved ≥5% BMI reduction during the run-in were then randomized to 52 weeks of exenatide XR 2.0 mg or placebo weekly.” PMID 35403350 ↗ Apr 2022 |
| Known as | Exenatide-LAR | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02811484 ↗ |
| Known as | exendin-4 | “Exenatide (Byetta [synthetic Exendin-4]; AstraZeneca, Wilmington DE) is a GLP-1 receptor agonist which reduces appetite and weight and may be an effective treatment in PWS.” NCT01444898 ↗5“In clinical testing in humans a recent randomized clinical study investigated the effect of Exendin-4 (Exenatide) on final infarct size in myocardial infarction.” NCT02673931 ↗ “Exenatide (synthetic exendin-4) is a subcutaneously injected GLP-1 receptor agonist” PMID 20152707 ↗ Mar 2010 “Exenatide is synthetic exendin-4, GLP-1 receptor agonist.” NCT01776788 ↗ “Recombinant Exendin-4 Injection” NCT03199261 ↗ |
| Known as | exentide-4 | “Exenatide (also known as exentide-4) infused after focal brain ischemia has been shown to reduce infarct volume in mice.” NCT02673931 ↗ |
| Known as | ExQW | “In trials, exenatide once weekly (ExQW), a GLP-1R agonist, improved glycemia, weight, blood pressure (BP), and lipids in patients with T2DM.” PMID 22566747 ↗ Apr 20121“exenatide once weekly extended-release (ExQW, Bydureon®)” NCT04520490 ↗ |
| Known as | ITCA 650 | “ITCA 650 (Exenatide in osmotic mini pump)” NCT02320045 ↗5“ITCA 650 is exenatide in DUROS” NCT01455922 ↗ “ITCA 650 is exenatide in DUROS” NCT01455896 ↗ “ITCA 650 is exenatide in DUROS” NCT01455883 ↗ “ITCA 650 is exenatide in DUROS” NCT01455870 ↗ “ITCA 650 is exenatide in DUROS” NCT01455857 ↗ |
| Known as | LY2148568 | “exenatide (LY2148568)” NCT00382239 ↗ |
| Known as | Presendin | “This trial has been designed to evaluate the efficacy and safety of a new formulation of exenatide (Presendin) in the reduction of intracranial pressure (ICP) in patients with IIH.” NCT05347147 ↗ |
| Known as | PT302 | “SR Exenatide (PT302)” NCT00964262 ↗ |
| Known as | PT320 | “Peptron has developed a sustained-release (SR)-Exenatide, (PT320, Q1W and Q2W), which has shown a higher Blood-Brain Barrier (BBB) penetration rate and better patient compliance.” NCT04269642 ↗ |
| Known as | SR-Exenatide | “Peptron has developed a sustained-release (SR)-Exenatide, (PT320, Q1W and Q2W), which has shown a higher Blood-Brain Barrier (BBB) penetration rate and better patient compliance.” NCT04269642 ↗1“SR Exenatide (PT302)” NCT00964262 ↗ |
| Action | Activate | “Exenatide, a glucagon-like peptide-1 receptor agonist, is used twice daily (BID)” PMID 22913891 ↗ Jul 2012 |
| Modality | Peptide | “Antibody formation to therapeutic peptides is common. This analysis characterizes the time-course and cross-reactivity of anti-exenatide antibodies and potential effects on...” PMID 22236356 ↗ Feb 2012 |
| Route | Subcutaneous | “All are subcutaneously injected twice daily” NCT00035984 ↗ |
| Target | GLP1R | “glucagon-like peptide-1 receptor agonist” PMID 22913891 ↗ Jul 2012 |